Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma prior to surgery. ClinicalTrials.gov. Updated October 26, 2022.

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acc ...

A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.

Mohs surgery significantly improved recurrence, metastasis, and mortality rates in patients with primary high-stage cutaneous cell carcinoma in a retrospective cohort study of 216 patients treated ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma.

However, conventional imaging methods occasionally fail to reflect disease changes in a timely manner [18], while blood biomarkers such as squamous cell carcinoma antigen (SCC-Ag) have limited ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Methods and analysis Patients diagnosed with FIGO (2009) stage IA1 (with lymphovascular space invasion), IA2 or IB1 cervical cancer with histological subtype of squamous cell carcinoma, adenocarcinoma ...

Early stage squamous cell vulvar cancer is the most common vulvar cancer and is diagnosed before it spreads. Treatment is highly effective.